Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-14
SponsorFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

About this trial

This study investigates how the immune system of children with celiac disease responds to controlled, small amounts of gluten. Children on a strict gluten-free diet are randomly assigned to receive either placebo, 50 mg of gluten, or 5 g of gluten once daily for three days, simulating real-life accidental exposure or dietary transgression. Blood samples are collected on Day 1 (before gluten intake) and Day 8 (five days after the last dose). Stool and urine samples are also collected for complementary analyses.

Using single-cell ribonucleic acid (RNA) sequencing, T-cell receptor sequencing, microRNA profiling, and exploratory metabolomics, the study aims to characterize changes in immune cell populations and gene expression after gluten exposure. The objective is to determine whether even very small amounts of gluten induce measurable systemic immune responses and whether these responses differ according to the dose administered. Understanding these mechanisms may support the development of new biomarkers and improve clinical management of pediatric celiac disease.

Eligibility criteria

Qualifiers

Age 8 to 14 years at study entry.

Diagnosis of celiac disease according to ESPGHAN 2020 criteria.

At least 18 months on a strict gluten-free diet (GFD).

Adequate adherence to the GFD, demonstrated by negative fecal gluten immunogenic peptides (GIP) prior to inclusion.

Disqualifiers

Obesity defined as BMI ≥ 95th percentile according to WHO criteria.

Diagnosed inflammatory bowel disease or diabetes mellitus.

Acute infectious illness at the time of inclusion.

Chronic hepatic, pulmonary, renal, or rheumatologic disease.

Trial design

Treatments tested in this trial

  • Placebo
  • Gluten 50 mg
  • Gluten 5 g
  • Collection of blood, stool and urine samples on Day 1 and Day 8.

Treatment groups

51 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Lead sponsor

Hospital Regional de Malaga

Collaborator

Andaluz Health Service

Collaborator

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Collaborator

Universidad de Málaga

Collaborator

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Collaborator

Biohealth Research Institute in Granada (ibs.GRANADA)

Collaborator